Granzyme B antibody | GB11

100% Secure


Mouse anti Granzyme B

Product Type
Monoclonal Antibody
Clone
GB11
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
MCA2120 C E F* IF IP 0.1 mg
Mouse anti Granzyme B antibody, clone GB11 recognizes the serine protease Granzyme B, which is important in the induction of apoptosis in target cells by cytolytic lymphocytes (CTLs).

Granzyme B plays a key role in the induction of apoptosis by CTLs. After delivery to the target cell, Granzyme B activates the cascade of caspases that finally results in cell death.

Mouse anti Granzyme B antibody, clone GB11 is suitable for the detection of Granzyme B expressing cells by flow cytometry. In normal peripheral blood approximately 20% of CD8+ve T cells have been found to express Granzyme B.

Product Details

Target Species
Human
Species Cross-Reactivity
Target SpeciesCross Reactivity
Chimpanzee
Monkey
Rhesus Monkey
N.B. Antibody reactivity and working conditions may vary between species.
Product Form
Purified IgG - liquid
Preparation
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Buffer Solution
Tris buffered saline
Preservative Stabilisers
0.09%Sodium azide
Immunogen
Purified human Granzyme B.
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Fusion Partners
Spleen cells from immunised Balb/c mice were fused with cells of the mouse SP2/0 myeloma cell line.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
18 months from date of despatch.

More Information

UniProt
P10144 Related reagents
Entrez Gene
GZMB Related reagents
GO Terms
GO:0005515 protein binding
GO:0001772 immunological synapse
GO:0004252 serine-type endopeptidase activity
GO:0005829 cytosol
GO:0005634 nucleus
GO:0006922 cleavage of lamin
GO:0019835 cytolysis
GO:0008629 induction of apoptosis by intracellular signals
GO:0008633 activation of pro-apoptotic gene products
Regulatory
For research purposes only

Applications of Granzyme B antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA 2ug/ml 5ug/ml
Flow Cytometry 1 1/10 1/100
Immunofluorescence
Immunohistology - Frozen
Immunoprecipitation
  1. 1 Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
ELISA
This antibody has been reported to function as a capture reagent in sandwich ELISA assays for soluble Granzyme B in conjunction with biotin conjugated GB10 as detection reagent.

Negative Isotype Controls Available

Description Product Code Pack Size Applications List Price Quantity
Mouse IgG1 Negative Control MCA928 100 Tests F

Application Based External Images

Immunohistology - Frozen

Product Specific References

References for Granzyme B antibody

  1. Spaeny-Dekking, E.H. et al. (1998) Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo.
    J Immunol. 160 (7): 3610-6.
  2. Tschopp, C.M. (2006) Granzyme B, a novel mediator of allergic inflammation: its induction and release in blood basophils and human asthma.
    Blood.108:2290-9.
  3. Wever, D. C. et al. (1998) The CD8+ Granzyme B+ T cell subset in peripheral blood from healthy individuals contains activated and apoptosis-prone cells.
    Immunol. 93: 383
  4. Hsi, B.L. & Yeh, C.J. (1986) Monoclonal antibodies to human amnion.
    J Reprod Immunol. 9 (1): 11-21.
  5. Mahrus, S. & Craik, C.S. (2005) Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells.
    Chem Biol. 12: 567-77.
  6. Davis, C.C. et al. (2010) Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.
    Cancer Res. 70: 5249-58.
  7. Hallermalm, K. et al. (2008) Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes.
    J Immunol. 180: 3766-74.
  8. Hufner, K. et al. (2009) Fewer latent herpes simplex virus type 1 and cytotoxic T cells occur in the ophthalmic division than in the maxillary and mandibular divisions of the human trigeminal ganglion and nerve.
    J Virol. 83: 3696-703.
  9. Kumar, D. et al. (2009) JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1.
    J Immunol. 182: 1011-20.
  10. Clayton, A. et al. (2008) Human tumor-derived exosomes down-modulate NKG2D expression.
    J Immunol. 180: 7249-58.
  11. Schleypen, J.S. et al. (2006) Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.
    Clin Cancer Res. 12: 718-25.
  12. Hodge, S. et al. (2015) Increased CD8 T-cell granzyme B in COPD is suppressed by treatment with low-dose azithromycin.
    Respirology. 20 (1): 95-100.
  13. Kumagai-Takei, N. et al. (2016) The Suppressed Induction of Human Mature Cytotoxic T Lymphocytes Caused by Asbestos Is Not due to Interleukin-2 Insufficiency.
    J Immunol Res. 2016: 7484872.